Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of RBP-6000 (Sublocade) in Opioid-Dependent Individuals
NCT02765867Phase 1Completed
- Sponsor
- Indivior
- Start
- Nov 2010
- Primary completion
- May 2011
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of buprenorphine extended-release injection in opioid use disorder (OUD), sponsored by Indivior. Primary endpoint: Treatment Emergent Adverse Events. Started Nov 2010; status: completed.
02
Drugs
buprenorphine extended-release injection
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT02765867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02765867.